Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Integrins are a superfamily of heterodimeric transmembrane receptors composed of non-covalently associated alpha and beta subunits that mediate cell-extracellular matrix (ECM) and cell-cell adhesion (Source: UniProt). They serve as critical mechanical and chemical links between the intracellular cytoskeleton and the extracellular environment, facilitating bidirectional signaling known as "inside-out" and "outside-in" signaling (Source: PubMed, PMID: 11882270). These processes regulate fundamental cellular activities, including survival, differentiation, and migration (Source: PubMed, PMID: 21867931). In various diseases, integrins are dysregulated; for instance, alpha-v-beta-3 (αvβ3) is often upregulated in tumor vasculature and certain cancers, promoting angiogenesis and metastasis (Source: Nature Reviews Cancer, 2010). In inflammatory conditions, integrins like alpha-4-beta-7 (α4β7) facilitate the recruitment of leukocytes to tissues (Source: Nature Reviews Immunology, 2007). Therapeutic interventions include monoclonal antibodies and small molecules designed to block these interactions, such as vedolizumab for inflammatory bowel disease and abciximab for preventing platelet aggregation in cardiovascular procedures (Source: StatPearls, 2023). However, targeting integrins can lead to significant safety concerns, such as increased bleeding risks or susceptibility to opportunistic infections like progressive multifocal leukoencephalopathy (Source: FDA, Tysabri Labeling).
Integrin antagonists or inhibitors block the binding of extracellular ligands (such as fibronectin, vitronectin, or ICAMs) to the integrin receptor, thereby preventing downstream signaling and cell adhesion.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Integrin (ITG) (ITG).